Collegium Pharmaceutical (COLL) Gains from Investment Securities (2014 - 2025)

Collegium Pharmaceutical's Gains from Investment Securities history runs 12 years deep, the most recent figure standing at -$19000.0 for Q4 2025.

• In Q4 2025, Gains from Investment Securities rose 99.35% year-over-year to -$19000.0; the TTM figure through Mar 2026 stood at -$3.7 million (down 0.51% YoY), while the FY2025 annual figure was $12.8 million, up 1498.94% from the prior year.
• Gains from Investment Securities was -$19000.0 for Q4 2025 at Collegium Pharmaceutical, down from $25836.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.8 million in Q4 2021 to a low of -$6.1 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged -$405134.3 across 5 years, with a median of $57918.0 in 2021.
• The sharpest annual moves came in 2021 and 2024: Gains from Investment Securities surged 612.71% in 2021, then sank 1350.64% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at $1.8 million in 2021, then tumbled by 434.84% to -$6.1 million in 2022, then soared by 103.82% to $233000.0 in 2023, then tumbled by 1350.64% to -$2.9 million in 2024, then jumped by 99.35% to -$19000.0 in 2025.
• The last three Gains from Investment Securities figures came in at -$19000.0 (Q4 2025), $25836.0 (Q3 2025), and $14949.0 (Q2 2025), per Business Quant data.